Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434014 | 0.87 | EGFR (0.40) | EPHX2NTRK1EGFRFGFR1KDR | |
| SCHEMBL21452672 | 0.87 | EPHX2 (0.43) | EPHX2EGFRFGFR1KDR | |
| SCHEMBL21452614 | 0.87 | EPHX2 (0.43) | EPHX2EGFRFGFR1KDR | |
| SCHEMBL21433996 | 0.87 | EPHX2 (0.43) | EPHX2EGFRFGFR1KDR | |
| SCHEMBL21453066 | 0.84 | KDM4E (0.40) | EPHX2SYKMAPTKDR | |
| SCHEMBL21452616 | 0.83 | CDK1 (0.41) | EPHX2EGFRFGFR1KDR | |
| SCHEMBL21452944 | 0.83 | CDK1 (0.41) | EPHX2EGFRFGFR1KDR | |
| SCHEMBL21452788 | 0.83 | KDM4E (0.40) | EPHX2SYKMAPTKDR | |
| SCHEMBL21433913 | 0.83 | EPHX2 (0.39) | EPHX2SYKEGFRFGFR1KDR | |
| SCHEMBL21452613 | 0.83 | EPHX2 (0.39) | EPHX2SYKEGFRFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |